AzTrials
AzTrials

Headache Disorders, PrimaryIHRSNCT05418218

International Headache Registry Study

An observational study of Headache Disorders, Primary and Headache Disorders, Secondary, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

In the International Headache and Vertigo Registration Study, patients aged 4-99 years with headache (primary headache and secondary headache such as migraine and tension type headache), vertigo (vertigo diseases such as vestibular migraine) and chronic pain (fibromyalgia and other diseases) were collected. Read more about this study

Who is it for?
Ages 4 to 99 yearsHealthy volunteers can take part
How many people
200,000 participants
Where
1 siteChina
Study dates
12 Jul 2021to 31 Dec 2082
How long will I take part?
60 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 4 to 99 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: Male or female participants ages 4 to 99 years

Who may be able to join

  • The following are requirements for entry into the study:
  • Written informed consent and participant privacy information (eg, Written Authorization for Use and Release of Health and Research Study Information) obtained from the participant prior to initiation of any study-specific procedures.
  • Male or female participants ages 4 to 99 years, inclusive, at Visit 1.
  • Headache patients meeting the diagnostic criteria for ICHD-3, including primary headaches such as migraine and tension tension-type headaches, secondary headaches, and patients who meet the headache diagnosis in the ICHD-3 appendix (including vestibular migraine).

Who cannot join

  • Patients who were unable to complete scales such as headache diary.
  • Patients denied or unable to be admitted for long-term follow-up.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Kaiming Liu, Doctor contact

+8615068862055

2314411@zju.edu.cn

China1 site, 1 recruiting
  • Kaiming Liu

    Hangzhou, Zhejiang, 370001

    Kaiming Liu

    Recruiting

Other trials in China

About this study

Official title: International Headache and Vertigo Registration Study

In the International Headache and Vertigo Registration Study, patients aged 4-99 years with headache (primary headache and secondary headache such as migraine and tension type headache), vertigo (vertigo diseases such as vestibular migraine) and chronic pain (fibromyalgia and other diseases) were collected. The biomarkers, imaging features, right-to-left shunt of the heart (lung), genetic characteristics, treatment, and outcome (in relation to other diseases) of headache-related diseases were studied, and long-term follow-up was planned.

Read the detailed description
  1. Research contents: In the International Headache and Vertigo Registration Study, patients aged 4-99 years with headache (primary headache and secondary headache such as migraine and tension type headache), vertigo (vertigo diseases such as vestibular migraine) and chronic pain (fibromyalgia and other diseases) were collected. The biomarkers, imaging features, right-to-left shunt of the heart (lung), genetic characteristics, treatment, and outcome (in relation to other diseases) of headache-related diseases were studied, and long-term follow-up was planned.
  2. Research target:

We study biomarkers, imaging features, right-to-left shunt of heart (lung), genetic features, real-world treatment studies, and outcomes (in relation to other diseases) for headache and vertigo related diseases.

Keywords
Migraine, Headache Disorders, Vertigo, Vestibular Migraine, Fibromyalgia
Medical subject headings
Headache Disorders, Primary, Headache Disorders, Secondary, Migraine Disorders, Tension-Type Headache, Vertigo, Fibromyalgia, Headache Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT05418218
Study groupRoleWhat they receive
MigrainePatients with migraine (including vestibular migraine), including all types of migraine as defined by ICHD-3.
Other Primary Headache DisordersPatients with other primary headache disorders (excluding migraine), including all types of other primary headache disorders (such as Tension-Type Headache, Cluster Headache) as defined by ICHD-3.
VertigoPatients with other vertigo disorders (excluding vestibular migraine).
Secondary Headache DisordersPatients with secondary headache disorders as defined by ICHD-3.
Normal controlNormal people do not have headache and vertigo.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Days of Migraine

    The number of days of migraine is the number of days in which migraine occurs or is likely to be migraine (according to IHS ICHD-3 diagnostic criteria).

    A migraine day is a day when a headache lasts for more than 30 minutes, does not take painkillers, and meets the ICHD-3 migraine or most likely migraine criteria. Migraine day can also be defined as a headache day that is effective for the acute treatment of specific migraine drugs (triptan, ditan, gepant, ergotamine, etc.).

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  2. Moderate / Severe Headache Days

    Moderate / severe headache days are defined as a day in which moderate or severe pain persists for at least 4 hours, or headache lasts for one day after successful medication for acute headache. These definitions allow the use of relatively simple headache diaries. Subjects were required to indicate whether headache was present (yes / no), peak (mild / moderate / severe) severity and duration (< 4h or 4h), type of acute drug intake (triptan ergot / other), and response to treatment should also be recorded.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  3. Migraine Attack

    Migraine attack is defined as any consistent migraine attacks or the use of specific migraine drugs. If a migraine attack is interrupted by sleep, or temporarily relieved, and then relapses within 48 hours, it is considered an attack. In addition, migraine attacks that were successfully treated with drugs but relapsed within 48 hours and lasted for more than 48 hours were counted as one attack.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

Secondary outcomes (26)
  1. The Response Rate of at Least 50%, 75% and 100% Reduction in the Number of Days of Migraine Attacks

    The response rate is calculated as the percentage reduction in the frequency of migraine attacks (or days of migraine, or days of moderate or severe headache) compared with the baseline during each treatment period. The response rate is traditionally defined as a reduction of at least 50% from the baseline, but other percentage reductions (for example: 30%, 75%, 100%) may be used.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  2. Headache Intensity

    Four-point rating scale was used to evaluate the headache intensity of each migraine day--painless, mild, moderate, or severe. Migraine intensity is not recommended as the main outcome measure alone, but it is important to record the decrease in migraine intensity as an indicator of disability reduction.

    Depending on the design of the trial, subjects should be asked to record the intensity of each migraine. In addition, the 11 point visual rating scale (VAS) can be used instead or in combination with the 4-level classification rating scale. The use of VAS in clinical trials may increase the likelihood of showing differences in severity.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  3. Cumulative Hours of Moderate / Severe Pain at 28 Days

    The cumulative number of hours of moderate / severe pain calculated by electronic headache diaries. If an attack occurs before going to bed and when you wake up, the amount of sleep also counts as the number of headache hours.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  4. Days Without Symptoms

    Defined as the number of days without aura, prodromal symptoms, headaches and subsequent symptoms. It needs to be determined by headache diary.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  5. Days Without Headache

    The number of days without headache also includes the number of days without related symptoms directly caused by migraine (including physical function, cognitive or emotional disorders).

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  6. Peak Headache Pain Intensity

    Subjects should record the maximum intensity of daily headaches and any medication used. An 11-point digital rating scale can be used instead of or in conjunction with a 4-level classified rating scale.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  7. Migraine Disability Assessment (MIDAS)

    MIDAS is a seven-item questionnaire designed to quantify headache-related disability within 3 months. The MIDAS score is the sum of days of absenteeism or absenteeism caused by headache, days of work or school plus days of housework, days without housework and days without non-work activities caused by headache in the last 3 months.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  8. Headache Impact Scale (HIT-6)

    HIT-6 is a six-question assessment scale used to assess the effects of headache on subjects' ability to work, school, housework and social tasks. The scale assessed the effects of headache on daily life and the functional ability of the subjects. The answer to the evaluation scale is based on the frequency of use of the 5-point scale from "never" to "often". The total score of HIT-6 ranges from 36 to 78, which is the sum of the scores between 6 (never) and 13 (often) for each question.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  9. Migraine Specific Quality of Life Questionnaire (MSQV2.1)

    MSQV2.1 is a 14-item questionnaire used to assess health-related quality of life decline due to migraine in the last 4 weeks. The questionnaire is divided into three areas: the role function limitation area, which is used to assess how migraine restricts the daily social and work-related activities of migraine patients; the role function block area, which is used to assess how migraine prevents these activities; and the emotional function area, which is used to evaluate the emotions associated with migraine. The subjects answered these items using a six-component scale from "never" to "at any time". The original dimension score was calculated by the sum of item answer scores and converted back to 0 to 100. The higher the score, the better the quality of life.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  10. Patient Health Questionnaire (PHQ-9)

    PHQ-9 is a validated, self-administered, concise tool for screening and diagnosis of mental health disorders, which has been tested in office practice. The screening scale is easy to use and can be completed in a short time, which improves the recognition rate of depression and facilitates the diagnosis and treatment of depression. PHQ-9 consists of 9 DSM-Ⅳ diagnostic criteria for depression in the last 2 weeks. Subjects were asked to use a 4-component scale to indicate the frequency of 9 depressive symptoms in the last 2 weeks: 0 (none at all), 1 (a few days), 2 (more than half) and 3 (almost every day). The total score ranges from 0 to 27 (from the best to the worst). A score of 15 to 19 indicates moderate to severe depression and a score of 20 to 27 indicates severe depression.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  11. Generalized Anxiety Disorder (GAD-7)

    GAD-7 is a proven, self-administered and concise tool for screening and diagnosing mental health disorders, which has been tested in the field in office practice. The screening scale is easy to use and can be completed in a short time, which improves the recognition rate of anxiety disorders and facilitates diagnosis and treatment. The main statistical index of this scale is the total score, that is, the sum of item scores. The total score range of GAD-7 is 0: 21 and that of GAD-2 is 0: 6. The score of GAD-7 can be used to evaluate the severity of anxiety symptoms: 0: 4: no clinical significance: anxiety: 5: 9: mild; 10: 14: moderate; > 15: severe. When used as an assistant diagnosis of anxiety symptoms, the cut-off value of GAD-7 is greater than or equal to 10.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  12. Functional Impairment Scale (FIS)

    Functional impairment scale (FIS) is a 4-point scale to evaluate the functional status and injury intensity in daily activities. It can be used in conjunction with the four-point pain intensity scale, usually done daily and summarized within four weeks.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  13. Euroqol-5 Dimension Questionnaire (EQ-5D)

    EQ-5D-5Lis a general tool for assessing health status. EQ-5D-5Lconsists of two parts of EQ-5D description system and EQ VAS. The description system consists of five dimensions (activity ability, self-care, daily activities, pain / discomfort and anxiety / depression). Respondents need to tick (or cross) the corresponding boxes of the most appropriate declaration for each of the five dimensions to indicate their health status. The score of the EQ-5D description system generally ranges from 0 (death) to 1 (completely healthy). EQ VAS recorded the respondents' self-rated health outcomes through a vertical visual simulation scale, and the two endpoints were "imaginable ideal health state" and "imaginable least ideal health state". EQ VAS scores range from 0 (the least ideal state of health imaginable) to 100 (the most ideal state of health imaginable).

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  14. Suicidal Ideation Score (C-SSRS Scale)

    Suicidal ideation should be monitored in trials of central action drugs, higher scores mean a worse outcome.

    Many migraine clinical trials used the Columbia suicide severity scale (C SSRS).The C-SSRS consists of a maximum of 20 items. C-SSRS will be administered in study subjects at each study visit to assess possible suicidal ideation and behavior. Reports of suicidal ideation with intent to act (endorse item 4 or 5) and reports of actual, aborted, or interrupted suicide attempts or a behavior preparatory for making an attempt indicate subjects at high risk for suicide.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  15. Pulse Rate

    Pulse rate will be measured during the visit.It means the number of heartbeats per minute, calculated with a stopwatch.Under normal circumstances, the pulse rate is consistent with the heart rate, and the normal range is 60-100 beats per minute. If it is greater than 100 beats per minute, it is called tachycardia. If it is less than 60 beats per minute, it is called bradycardia.

    Record whether the pulse rate is normal, and describe in detail if abnormal. Record the number of people with clinically significant abnormal pulse rate.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  16. Respiratory Rate

    Respiratory rate will be measured during the visit.It means the number of breaths per minute, calculated with a stopwatch.Clinically, one inhalation and one exhalation are defined as one breath. The normal breathing rate is 12-20 breaths per minute.

    Record whether the respiratory rate is normal, and describe in detail if abnormal.

    Record the number of people with clinically significant abnormal respiratory rate.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  17. Blood Pressure

    Blood Pressure will be measured during the visit,including systolic blood pressure(SBP) and diastolic blood pressure(DBP). It can be calculated with a sphygmomanometer.

    Blood pressure level classification for adults over 18 years old: normal blood pressure (SBP<120 mmHg and DBP<80 mmHg), high normal value [SBP 120-139 mmHg and (or) DBP 80-89 mmHg], hypertension [SBP≥140 mmHg] and (or) DBP≥90 mmHg].

    Record whether the blood pressure is normal, and describe in detail if abnormal.

    Record the number of people with clinically significant abnormal blood pressure.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  18. Body Temperature

    Body temperature will be measured during the visit.It can be calculated with a thermometer.The normal armpit body temperature of an average adult is 36-37°C.

    Record whether the body temperature is normal, and describe in detail if abnormal.

    Record the number of people with clinically significant abnormal body temperature.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  19. Body Mass Index (BMI)

    The following measurements are to be performed: height (initial screening only) and weight. Height and weight are to be measured without shoes. Body Mass Index (BMI) should be calculated using the following formula: BMI (kg/m2= weight (kg)/[height (cm)/100]2.

    A normal BMI is between 20 and 25, over 25 is overweight and over 30 is obese.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  20. Magnetic Resonance Imaging(MRI) T1

    Patients will accept MRI scans. MRI T1 imaging data and description given by professional radiologist will be collected.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  21. MRI T2

    Patients will accept MRI scans. MRI T2 imaging data and description given by professional radiologist will be collected.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  22. MRI T2 FLIAR

    Patients will accept MRI scans. MRI T2 FLIAR imaging data and description given by professional radiologist will be collected.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  23. Susceptibility weighted imaging(SWI) in MRI

    Patients will accept MRI scans. SWI imaging data and description given by professional radiologist will be collected.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  24. Arterial spin labeling(ASL) in MRI

    Patients will accept MRI scans. ASL imaging data and description given by professional radiologist will be collected.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  25. Diffusion Tensor Imaging(DTI) in MRI

    Patients will accept MRI scans. DTI imaging data and description given by professional radiologist will be collected.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

  26. Echocardiography

    Patients will accept Echocardiography. The degree of Right-to-left Shunt will be collected.

    Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jun 2022
  2. Study start12 Jul 2021
  3. Primary completion31 Dec 2082 (estimated)
  4. Study completion31 Dec 2082 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
200,000 participants (estimated)
Target duration
60 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT05418218
Sponsor's protocol ID
20220430
Acronym
IHRS
Status last verified
Oct 2024
First submitted
30 Apr 2022
Last updated
23 May 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Headache Disorders, Primary and Headache Disorders, Secondary, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 23 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Kaiming Liu, Doctor (+8615068862055, 2314411@zju.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Days of Migraine (time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 May 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in